Drug Discovery World

FEBRUARY 23, 2023

Spanish pharma company Ferrer and Swiss biotech Asceneuron have signed a licensing agreement giving Ferrer the rights to ASN90 in progressive supranuclear palsy (PSP), an orphan, tau-related disease with a high unmet medical need.

Drugs 52

Drugs Licensing Licensing Protein 52

Drug Discovery World

APRIL 20, 2023

Dr Paula Moran, Dr Kiri Granger, Dr J Mark Treherne , and Dr Jenny Barnett explore the effects of long Covid-19 symptoms and what the opportunities are for drug developers working to treat post-Covid-19 cognitive impairment. developed dementia over the subsequent two years (vs. Notably, among over-65s who had had Covid-19, 4.5%

Development 98

Development Drugs Clinical Trials Clinical Trials 98

Pharmaceutical Technology

AUGUST 1, 2022

Since 2020, government agencies have provided funding for expensive late-stage vaccine development and the expansion of manufacturing capacity, as well as other key pharmaceutical activities. The shift from private to public funding enabled more rapid development of Covid-19 drugs and vaccines.

Vaccination 234

Vaccination Vaccine Bacteria Life Science 234

pharmaphorum

FEBRUARY 3, 2022

India’s Dr Reddy’s Laboratories has joined the growing list of pharma companies that are looking to tap into the market for medical cannabis, buying German developer Nimbus Health for an undisclosed sum. The two drugs were developed by medical cannabis pioneer GW Pharma, which was acquired by Jazz last year.

Licensing 117

Licensing Licensing Marketing Medicine 117

pharmaphorum

NOVEMBER 29, 2021

.” It says the interested parties include UK biotech Oxford BioMedica, Swiss chemicals group Lonza, and Japan’s Fujifilm, which has subsidiaries that provide contract development and manufacturing services to the pharma industry.

Vaccination 103

Vaccination Vaccine Manufacturing Pharma Companies 103

pharmaphorum

MAY 4, 2022

In testing new treatments, what is promising in animal models may not transfer particularly well to humans, which helps to explain why there is a 90% failure rate during clinical development. Quris has taken its technology and used it to develop its own drug candidate pipeline. Nascent technology.

Drugs 143

Drugs Licensing Licensing Pharma Companies 143

World of DTC Marketing

APRIL 12, 2021

The goal of getting a drug to market as fast as possible so they can recoup drug development costs has the potential for mistakes that could cost lives. Coupled with all this is the continued outsourcing of raw materials and other steps in drug development. We can’t continue to develop drugs the same way as we have done before.

Generic Drugs 187

Generic Drugs Manufacturing Production Drugs 187

Drug Discovery World

FEBRUARY 5, 2024

However, two-thirds (68%) of patients are comfortable receiving medicines before they’re licensed through their country’s healthcare system. The new data was released by pharma company Clinigen to mark the start of Rare Disease Month.

Medicine 52

Medicine Pharma Companies Licensing Licensing 52

pharmaphorum

DECEMBER 22, 2021

Gyroscope Therapeutics and its gene therapy for the sight-robbing disease geographic atrophy (GA) has been acquired by a big pharma company – but likely not the one you would expect. Last year, it also signed a licensing deal with Dyno Therapeutics for its AAV capsid-based gene delivery technology focused on ocular diseases.

Gene Therapy 104

Gene Therapy Gene Licensing Licensing 104

Pharmaceutical Technology

SEPTEMBER 2, 2022

In a recent report, GlobalData revealed that the US Food and Drug Administration (FDA) approved 122 new drug applications (NDAs) and biologic license applications (BLAs) in 2021. There are many reasons why a company might prefer to keep commercialisation activities inhouse. The rate of drug approvals could be on the rise.

Drugs 130

Drugs Pharma Companies Sales Production 130

pharmaphorum

SEPTEMBER 20, 2022

The big pharma company is making a $20 million investment in the Israeli startup along with funding that could reach $90 million over the next five years, in a return for options to license CytoReason’s AI platform and disease models.

Pharma Companies 52

Pharma Companies Trials Engineer Development 52

pharmaphorum

JANUARY 8, 2021

There’s a new player in the neurology and mental health drugs market after Italy’s Angelini Pharma merged with Switzerland’s Arvelle Therapeutics in a deal worth up to $960 million based around the anti-seizure drug cenobamate. It is already in the late stages of development and expected to be approved in Europe later this year.

Licensing 52

Licensing Licensing Pharma Companies Branding 52

pharmaphorum

MAY 20, 2022

The new initiative – called ATOM (Access to Oncology Medicines) – pledges to tackle the issue that fewer than 50% of the cancer medicines on the World Health Organization’s essential medicines list are available in developing nations around the world. million in 2020 to 4 million by 2040, according to ATOM’s members. .”

Drugs 109

Drugs Medicine Licensing Licensing 109

pharmaphorum

DECEMBER 21, 2021

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene. Pharma companies are looking at whether blocking TIGIT as well as PD-1/PD-L1 can improve the efficacy of cancer immunotherapy.

Drugs 98

Drugs Antibody Pharma Companies Development 98

pharmaphorum

DECEMBER 6, 2022

$500 million upfront and a total deal value of up to $5 billion sounds like a deal made by a top-tier pharma company – but in fact it comes from diminutive biotech Summit Therapeutics. The post Little Summit Therapeutics spends big bucks to rebuild pipeline appeared first on.

Licensing 52

Licensing Licensing Antibody Clinical Trials 52

pharmaphorum

JUNE 4, 2021

At the moment, Xofigo is the only approved TAT on the market, but Bayer is also developing a pipeline of other candidates based on thorium-227 linked to antibodies or small-molecule drugs. The technology behind the drug was licensed from Weill Cornell Medicine and Johns Hopkins University in the US.

Antibody 81

Antibody Licensing Licensing Protein 81

pharmaphorum

FEBRUARY 13, 2022

German drugmaker Merck KGaA has reached an agreement to pilot an artificial intelligence platform developed by Quris that aims to identify potential safety problems with new therapeutic candidates as early as possible in the drug discovery process.

Drugs 98

Drugs In-Vivo In-Vitro Pharma Companies 98

pharmaphorum

JANUARY 7, 2022

If the last couple of days is an indication, 2022 is already shaping up to be the year of big-ticket alliances between big pharma companies and specialists in artificial intelligence-driven discovery. billion if the full tally of small-molecule candidates for make it through development. Shortly after Amgen unveiled its $1.9

Drugs 109

Drugs Pharma Companies Medicine Licensing 109

pharmaphorum

APRIL 22, 2021

In a filing with the Securities and Exchange Commission, Centessa said it plans to use proceeds to fund the development of the 16 drugs in its pipeline, as well as potential acquisitions. The company has an “asset focused” R&D philosophy , where development is centred on the needs of each individual biotech.

Licensing 64

Licensing Licensing Pharma Companies Drugs 64

Camargo

SEPTEMBER 23, 2020

The panelists brought diverse perspectives on the future of orphan drug development, how their companies evaluate new potential products and partnering opportunities, and how they are working to address challenges like clinical study design and patient recruitment. Thomas Kassberg, Chief Business Officer, Ultragenyx.

Business Development 136

Business Development Drugs Development Production 136

pharmaphorum

FEBRUARY 12, 2021

While Novartis is shoring up its position in generic antibiotics, the drugmaker decided the pursuit of new drugs that might help stem the rising tide in antimicrobial resistance (AMR) was too challenging, joining several other big pharma companies – including AstraZeneca, Roche, Bristol-Myers Squibb and Eli Lilly – in ducking out of the field.

Drugs 109

Drugs Sales Pharma Companies Marketing 109

pharmaphorum

APRIL 21, 2022

One of the leading companies in the bid to bring a new class of alpha-synuclein targeting drugs to market for Parkinson’s disease – AbbVie – is ducking out of the challenge. ” She added that BioArctic will now “investigate options to continue the development of this asset.”

Antibody 97

Antibody Protein Gene Therapy Pharma Companies 97

pharmaphorum

JUNE 14, 2021

Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a much-needed drug for this rare disease, and explores how regulators and pharma companies can help make patient involvement in HTA more impactful. The earlier HTAs, researchers and pharma companies can start that engagement the better.

Drugs 105

Drugs Pharma Companies Licensing Licensing 105

pharmaphorum

JANUARY 6, 2022

The latest pharma company to make a move for an mRNA specialist is Germany’s Merck KGaA, which has offered a $780 million cash buyout to US biotech Exelead. Exelead was part of that success, helping to manufacture vaccine precursors for the Pfizer/BioNTech shot Comirnaty.

Vaccination 98

Vaccination Vaccine Manufacturing Life Science 98

pharmaphorum

JANUARY 20, 2022

The mission to treat people who suffer from allergic rhinitis has been given a boost as two pharma companies join forces. Ryaltris, which was developed by Glenmark, is a novel, fixed-dose combination nasal spray of an anti-histamine (olopatadine hydrochloride) and a steroid (mometasone furoate). with allergic rhinitis.

Allergies 70

Allergies Marketing Manufacturing Production 70

pharmaphorum

OCTOBER 7, 2021

The factory will be able to supply up to 500 million doses of mRNA shots a year, and cover the full spectrum of manufacturing from drug substance production through to full/finish and packaging, according to the company. According to the latest WHO data, just 4.4%

Vaccination 98

Vaccination Vaccine Manufacturing Packaging 98

pharmaphorum

OCTOBER 28, 2020

Data defines modern therapeutics, but this is almost uniquely confined to the clinical trial stages of drug development. Identifying, recruiting, retaining and monitoring patients during this part of the cycle is estimated to cost pharma US$19 billion a year as companies seek to harvest patient experiences.

Medicine 117

Medicine Pharma Companies Vaccination Vaccine 117

pharmaphorum

JANUARY 24, 2023

Tech company CytoReason has announced it has signed a multi-year, multimillion dollar deal with Sanofi to deliver artificial intelligence (AI) for drug discovery and development in the field of inflammatory bowel disease (IBD). The collaboration takes CytoReason’s partnering with leading pharmaceutical companies to a total of five.

Medicine 52

Medicine Drugs Pharma Companies Licensing 52

pharmaphorum

DECEMBER 16, 2022

Further, with a pandemic treaty in development, there are reasons to believe that many countries and the WHO want to see a more equitable distribution of medical products for future pandemics. The industry has so far resisted demands for the sharing of intellectual property (IP) around products developed to counter the pandemic.

Vaccination 96

Vaccination Vaccine Production Licensing 96

pharmaphorum

MAY 17, 2021

UK biotech Arecor Therapeutics has announced plans to float on the London stock market, to fund plans to develop novel formulations of insulins and other biological drugs with enhanced properties. Arecor has four active licensing agreement in place with partners including Hikma and Inhibrx.

Insulin 52

Insulin Production Marketing Pharma Companies 52

pharmaphorum

DECEMBER 9, 2022

SHP2 has become a popular target among cancer drug developers, as it lies upstream of other molecular pinch points, like RAS/ERK MAPK which drive cellular proliferation and survival. Going forward, our strategy for developing RMC-4630 is unaffected by [Sanofi’s] decision,” said Revolution’s chief executive, Mark Goldsmith.

Pharma Companies 57

Pharma Companies Licensing Licensing Trials 57

pharmaphorum

MAY 13, 2022

The deal marks growing interest in SHP2 as a target among cancer drug developers, inspired by the promise of targeting cancer-associated molecular pathways upstream of other targets like RAS/ERK MAPK, which drive cellular proliferation and survival.

Drugs 57

Drugs Pharma Companies Licensing Licensing 57

pharmaphorum

JUNE 11, 2021

The Philadelphia-based company said it had taken the decision to go down the biologics license application (BLA) route for Covaxin based on FDA feedback to the EUA data package it had submitted to the agency. Bharat has also reported data suggesting the shot is effective against the beta (B.1.351) 1.351) variant.

Vaccination 83

Vaccination Vaccine Licensing Licensing 83

pharmaphorum

SEPTEMBER 23, 2021

AstraZeneca has joined the ranks of big pharma companies bolting on RNA-based technology platforms in the wake of the stellar success of mRNA vaccines for COVID-19. Along with the equity investment and milestones, AZ will also provide R&D funding to projects that enter into development.

RNA 52

RNA Immune Response Vaccination Vaccine 52

Delveinsight

AUGUST 2, 2020

The company has also signed a licensing agreement with Ono Pharmaceutical , a Japanese pharma company, transferring exclusive rights to develop and commercialise anamorelin in Japan, South Korea, and Taiwan. Cancer Cachexia Pipeline. Apart from the products as mentioned earlier, Tetra Bio?Pharma,

Marketing 94

Marketing Pharma Companies Development Hormones 94

pharmaphorum

SEPTEMBER 29, 2020

As of 2018, there were over 1,100 cancer therapies in development, and as of 2020, 362 of them were cell and gene therapies. As a result, there is a need for continued innovation and increased efficiency in terms of drug development to manage cost, complexity and speed to provide potentially transformative therapies for cancer patients.

Research 132

Research Gene Editing Gene Development 132

pharmaphorum

SEPTEMBER 20, 2021

For the pharma industry, the pandemic’s changes were both abrupt and industry-altering, requiring companies to rapidly adapt their approaches to drug development and commercialisation. Analytics tools managed by the pharma sales team can be valuable for tracking physician preferences when developing your omnichannel approach.

Sales 98

Sales Marketing Pharma Companies Licensing 98